Pharmacokinetics Of CP-690,550 In Pediatric Patients With Juvenile Idiopathic Arthritis (JIA)

Completed · Phase 1

Conditions studied: Juvenile Idiopathic Arthritis

In brief

Phase 1 study to describe pharmacokinetics of CP-690,550 in pediatric patients 2 to less than 18 years of age with Juvenile Idiopathic Rheumatoid Arthritis (JIA).

Key facts

Study ID

NCT01513902

Run by

Pfizer

People needed

26

Starts

2013-03-01

Expected to finish

2015-12-01

Last updated by the study team

2016-07-04

Who can join

Age: 2 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Pediatric patients with JIA aged from 2 to less than 18 years with active JIA (extended oligoarthritis, polyarthritis rheumatoid factor positive or negative, psoriatic arthritis, enthesitis related arthritis), in 5 or more joints (using American College Rheumatology definition of active joint) at the time of the first study drug administration.
• For subjects receiving MTX treatment, minimum duration of therapy is 4 months and dose stable for at least 6 weeks prior to first dose of study drug. MTX may be administered either orally or parenterally at doses not to exceed 20 mg/wk or 15 mg/m2/week.
• A negative QuantiFERON-TB Gold In-Tube test performed within the 3 months prior to screening. A negative PPD test can be substituted for the QuantiFERON-TB Gold In-Tube test only if the central laboratory is unable to perform the test or cannot determine the results to be positive or negative and the Pfizer medical monitor approves it, on a case-by-case basis.

You may not qualify if…

• Systemic JIA, persistent oligoarthritis, undifferentiated arthritis.
• Current or recent history of uncontrolled clinically significant renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, or neurological disease.
• History of any other rheumatic autoimmune disease.
• Infections:
• Latent or active TB or any history of previous TB.
• Chronic infections.
• Any infection requiring hospitalization, parenteral antimicrobial therapy or judged to be opportunistic by the investigator within the 6 months prior to the first dose of study drug.
• Any treated infections within 2 weeks of Baseline visit.
• A subject known to be infected with human immunodeficiency virus (HIV), hepatitis B or hepatitis C virus.
• History of infected joint prosthesis with prosthesis still in situ.
• History of recurrent (more than one episode) herpes zoster or disseminated (a single episode) herpes zoster or disseminated (a single episode) herpes simplex.
• The biologic agents and DMARDs are disallowed at any time during this study. If a subject needs to be treated with one of these agents, the subject should be discontinued from the study.
• Subjects who have been vaccinated with live or attenuated vaccines within the 6 weeks prior to the first dose of study medication or is to be vaccinated with these vaccines at any time during treatment or within 6 weeks following discontinuation of study drug.
• Subjects with a malignancy or with a history of malignancy with the exception of adequately treated or excised non-metastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in situ.

Where it is running

• Explorer Clinic, University of Minnesota Children's Hospital — Minneapolis, Minnesota, United States
• Clinical and Translational Science Institute Masonic Clinical Research Unit (Administration Only) — Minneapolis, Minnesota, United States
• Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio, United States
• Randall Children's Hospital at Legacy Emanuel — Portland, Oregon, United States
• PRI - Pediatric Rheumatology Research Institute GmbH — Bad Bramstedt, Germany
• Hamburger Zentrum fuer Kinder-und Jugendrheumatologie SchoenKlinik Hamburg Eilbek — Hamburg, Germany
• Asklepios Klinik Sankt Augustin Gmbh — Sankt Augustin, Germany
• Wojewodzki Specjalistyczny Szpital Dzieciecy im. Sw. Ludwika w Krakowie — Krakow, Poland
• Klinika Kardiologii i Reumatologii Dzieciecej — Lodz, Poland
• Narodny ustav reumatickych chorob — Piešťany, Slovakia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.